<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugs_disease_country/PMC7265527/results/search/drugs/results.xml">
  <result pre="approved influenza antivirals were viral neuraminidase inhibitors2,3. Of these, only" exact="oseltamivir" post="(Tamiflu) can be taken orally, thereby facilitating its widespread"/>
  <result pre="the last step in the production of infectious virus. Multiple" exact="oseltamivir" post="treatments over 5 consecutive days are required to fully"/>
  <result pre="treatment10,11 (Supplementary Fig. 1). We estimated the efficacy with which" exact="oseltamivir" post="and baloxavir inhibit viral replication by fitting the model"/>
  <result pre="shows that baloxavir inhibits influenza virus replication more effectively than" exact="oseltamivir" post="(Fig. 1). Within 1 day of initiating baloxavir or"/>
  <result pre="oseltamivir (Fig. 1). Within 1 day of initiating baloxavir or" exact="oseltamivir" post="treatment, virus load decreases by an estimated 84% or"/>
  <result pre="in the clinical trial, including the initiation of baloxavir or" exact="oseltamivir" post="regimens at different times after symptom onset (Supplementary Fig."/>
  <result pre="\usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document} ϵ for" exact="oseltamivir" post="0.89 0.88 0.90 Initial sensitive viral load V0 (TCID50/ml)"/>
  <result pre="observations8 among patients treated with a baloxavir (427 patients), b" exact="oseltamivir" post="(377 patients), or c placebo (210 patients). Day zero"/>
  <result pre="Reduction of infectiousness by treatment with a baloxavir or b" exact="oseltamivir" post="compared with treatment with placebo. Patients were assumed to"/>
  <result pre="3a). Treatment of 30% of infected cases with baloxavir or" exact="oseltamivir" post="within 48 h after symptoms onset reduces the expected number"/>
  <result pre="predicted to reduce the overall burden of influenza more than" exact="oseltamivir" post="treatment across all treatment rates. If half of all"/>
  <result pre="rates. If half of all cases are treated, baloxavir or" exact="oseltamivir" post="are expected to reduce incidence by 58% or 39%,"/>
  <result pre="(black) or with 30% of cases receiving baloxavir (blue) or" exact="oseltamivir" post="(green) treatment. Lines indicate a moving 10-day average of"/>
  <result pre="baloxavir treatment and the increased benefit of baloxavir relative to" exact="oseltamivir" post="are greatest in the first 24 h period (Fig. 4a)."/>
  <result pre="treating the indicated percent of cases with either baloxavir or" exact="oseltamivir" post="within 48 h of symptom onset. For both graphs, the"/>
  <result pre="influenza-associated mortality and morbidity averted by scaling up baloxavir or" exact="oseltamivir" post="treatment (Fig. 4c). Specifically, we calculate the reduction in"/>
  <result pre="and mortality (38%). Clinical trial8 results indicate that baloxavir and" exact="oseltamivir" post="reduce the duration of illness by at least 23 h."/>
  <result pre="decreases with baloxavir treatment to a greater extent than with" exact="oseltamivir" post="treatment (Fig. 4c). For example, when only 20% of"/>
  <result pre="is expected to avert one DALY, whereas 18.6 courses of" exact="oseltamivir" post="treatment are needed to avert one DALY. Hence, each"/>
  <result pre="to avert one DALY. Hence, each course of baloxavir or" exact="oseltamivir" post="treatment is expected to prevent the loss of ~5"/>
  <result pre="higher mortality rates24. The relative benefits of mass treatment with" exact="oseltamivir" post="and baloxavir that we have estimated for seasonal influenza"/>
  <result pre="treatment is predicted to yield a higher herd effect than" exact="oseltamivir" post="(Supplementary Fig. 6). Seminal studies of the mitigation of"/>
  <result pre="the pandemic virus29,30. Our new estimates of time-dependent baloxavir and" exact="oseltamivir" post="efficacy against virus spread are qualitatively consistent with these"/>
  <result pre="al.Strategies for mitigating an influenza pandemicNature200644244845210.1038/nature0479516642006 30.KamalMAet al.Interdisciplinary pharmacometrics linking" exact="oseltamivir" post="pharmacology, influenza epidemiology and health economics to inform antiviral"/>
  <result pre="ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT03684044 (2018). 36.KamalMAet al.A drug-disease model describing the effect of" exact="oseltamivir" post="neuraminidase inhibition on influenza virus progressionAntimicrob. Agents Chemother.2015595388539510.1128/AAC.00069-1526100715 37.MeyersLAPourbohloulBNewmanMEJSkowronskiDMBrunhamRCNetwork"/>
 </snippets>
</snippetsTree>
